Efron Paul 4

What Happened

• Efron Paul, a director of Keenova Therapeutics plc, settled restricted stock units (RSUs) on June 2, 2026. The filing reports conversion/exercise-type derivative activity for 3,580 RSUs.
• Of the reported activity, 825 ordinary shares were withheld to satisfy tax withholding obligations and 2,930 RSUs were forfeited/returned to the issuer under an agreement. Transaction prices are listed as N/A or $0.00 and no open-market sale or purchase occurred.

Key Details

• Transaction date: 2026-06-02; Form filed: 2026-06-04 (appears timely).
• Reported items: conversion/exercise of 3,580 RSUs; 825 shares withheld for taxes (disposition code F); 2,930 RSUs forfeited/returned to issuer (disposition code D).
• Price/value: reported as N/A or $0.00 for the derivative settlement; issuer notes its ordinary shares are not listed/quoted on a recognized market.
• Footnotes of note:
  • Each settled RSU was converted one-for-one into ordinary shares (F1).
  • Withholding (825 shares) was based on a percentage and did not use a market value because the shares are unlisted (F2).
  • The reporting person forfeited 2,930 RSUs in exchange for a payment from the issuer to help satisfy certain tax obligations related to the RSUs (F3).
  • The RSUs were originally granted 8/14/2025 and vest on the earlier of the first anniversary or the next AGM (F4, F5).
• Shares owned after the transaction are not specified in the provided filing excerpt.

Context

• This was not an open-market sale or purchase; it was an internal settlement of RSUs with tax withholding and a forfeiture arrangement. Such settlements are routine compensation events and do not necessarily signal a buy/sell investment decision.
• For retail investors: note the filing documents award settlement mechanics (conversion, withholding, forfeiture), not evidence of directional insider buying or market sales.